Nanotherapeutics IN VIVO Reprogramming

About Us


Dr. Frederick S. Hagen
Chief Executive Officer

Dr. Hagen is a serial entrepreneur. During his tenure at ZymoGenetics, he experienced first-hand the development and maturation of a biotechnology company from startup through buyout by Novo Nordisk. Major accomplishments at ZymoGenetics include cloning and expression of the cDNA for Factor VII. This blood coagulation protein, NovoSeven®, has had life-time sales of over $23 billion. Dr. Hagen spent a year at Novo Nordisk headquarters in Copenhagen, Denmark, during the development of NovoSeven®, where he gained experience in the operations of a large pharmaceutical company.

After ZymoGenetics, Dr. Hagen founded Icogenex Corporation. While CEO of Icogenex, he negotiated 9 contract projects with other pharma and biotech companies and Icogenex received funding on 19 grants from National Institutes of Health (NIH). Dr. Hagen founded Icogenex Bioincubator that has incubated over 80 biotech startups since 2002 with aggregate IPO capitalization of $4.4 billion for 6 of these companies. As CEO of Stemgenics, Dr. Hagen has lead Series A and B financing rounds totaling $4 million. Dr. Hagen received his Ph.D. from the University of Washington, completed his postdoctoral work at Harvard Medical School with Dr. Alice Huang and recombinant DNA training with Nobel Laureate Dr. David Baltimore at MIT. He has 21 issued patents and 34 peer review publications.

Dr. Andranik Andrew Aprikyan
Founder, Chief Scientific Officer (CSO), and Vice President

Dr. Aprikyan is a Co-Founder and the inventor of the Stemgenics multi-specific nanoparticle reprogramming technologies. Dr. Aprikyan serves as Chief Scientific Officer and Executive Vice President at Stemgenics. Formerly, he was on the faculty at the School of Medicine Hematology/Oncology, University of Washington for nearly 20 years. Dr. Aprikyan’s 30+ years of research and teaching experience mostly at the University of Washington School of Medicine first as a Senior Postdoctoral Fellow, and then as Research Assistant Professor of Medicine and an Ambassador for the American Cancer Society set the stage for his recent discoveries. Prior to the University of Washington, Dr. Aprikyan was a Lead Investigator in the Department of Neurochemistry of Aging at the Institute of Biochemistry, Yerevan, Armenia. Dr. Aprikyan’s research was focused on molecular and cellular mechanisms underlying development of inherited and acquired diseases associated with severe neutropenia and leukemia, correction of pathological conditions triggered by various gene mutations, and therapeutic potential of human pluripotent stem cells, bone marrow stem/progenitor cells and more specialized cell types.

Dr. Aprikyan’ research was funded by a number of private and federal grants awarded by the American Cancer Society, Amgen, NCI, NHLBI, NIAID and NIDDK. He served as an ad hoc member of the NIH study sections on Translational Medicine and Stem Cells. He also served as a member of Review Boards and Moderator of scientific sessions at several major national and international biomedical forums. Dr. Aprikyan has more than 80 scientific publications, and he served as Associate Editor and reviewer for several prestigious peer-reviewed journals. His research and recent scientific discoveries led to the development of the Stemgenics multi-functionalized cell-penetrant nanoparticle reprogramming technologies for targeted control of cell fate and functions. Dr. Aprikyan is an inventor on 14 issued and pending patents. In his spare time, Dr. Aprikyan likes swimming, hiking, and skiing with his family and friends. He is a competitive table tennis player and a recipient of several national and international prizes.

Scientific Advisors/Consultants

H. Joachim Deeg, MD

Dr. Deeg is a Professor of Medicine, University of Washington and a Member of Clinical Research Division, Fred Hutchinson Cancer Research Center (FHCRC). He has treated many cancer patients with stem cell therapy and successfully prosecuted a number of clinical protocols through FDA approval.

Carol Ware, Ph.D.

Dr. Ware is Professor of Comparative Medicine and Director of the Tom and Sue Ellison Stem Cell Core and Associate Director of the Institute of Stem Cell and Regenerative Medicine, University of Washington. Her research has focused on pluripotent stem cells for over 30 years and currently focuses on induction of pluripotency and the factors that control the maintenance of pluripotency.

Aravind Ramakrishnan, MD

Dr. Ramakrishnan is Assistant Member of the FHCR and Assistant Professor of Medicine at the University of Washington. Dr. Ramakrishnan is an expert on mature cell reprogramming into stem cells using lenti-viruses and episomal vectors.

Zaza Khuchua, Ph.D.

Dr. Khuchua is Associate Professor of Pediatrics/Molecular Cardiology, University of Cincinnati, OH. Dr. Khuchua is an established expert in cardiovascular biology and cardiac physiology.